Invion Ltd - Asset Resilience Ratio
Invion Ltd (IVX) has an Asset Resilience Ratio of 8.96% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IVX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2022)
This chart shows how Invion Ltd's Asset Resilience Ratio has changed over time. See Invion Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Invion Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Invion Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$850.37K | 8.96% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$850.37K | 8.96% |
Asset Resilience Insights
- Limited Liquidity: Invion Ltd maintains only 8.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Invion Ltd Industry Peers by Asset Resilience Ratio
Compare Invion Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Invion Ltd (2002–2022)
The table below shows the annual Asset Resilience Ratio data for Invion Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 42.28% | AU$8.47 Million ≈ $6.00 Million |
AU$20.04 Million ≈ $14.18 Million |
+23.90pp |
| 2021-06-30 | 18.38% | AU$1.04 Million ≈ $733.62K |
AU$5.64 Million ≈ $3.99 Million |
+2.59pp |
| 2017-06-30 | 15.79% | AU$917.49K ≈ $649.18K |
AU$5.81 Million ≈ $4.11 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$11.98 Million ≈ $8.48 Million |
-- |
| 2007-06-30 | 42.43% | AU$1.58 Million ≈ $1.12 Million |
AU$3.74 Million ≈ $2.64 Million |
-29.52pp |
| 2002-06-30 | 71.95% | AU$1.07 Million ≈ $754.97K |
AU$1.48 Million ≈ $1.05 Million |
-- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more